scispace - formally typeset
A

Axel Ullrich

Researcher at Max Planck Society

Publications -  436
Citations -  63142

Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.

Papers
More filters
Journal ArticleDOI

Differential expression of MAM-subfamily protein tyrosine phosphatases during mouse development

TL;DR: A detailed analysis of their mRNA transcript distributions at different stages of mouse embryogenesis and postnatal brain development revealed distinct and complementary expression patterns of PTPkappa, PTPmu and PCP2 transcripts, and discusses MAM-PTPases as a new class of morphoregulatory molecules.
Journal ArticleDOI

Drug Discovery in the Kinase Inhibitory Field Using the Nested Chemical Library™ Technology

TL;DR: Biochemical kinase inhibitory assays on selected, cloned kinase enzymes for a few hundred NCL compound sets can provide sufficient biological data for rational computerized design of new analogues, based on the pharmacophore model-generating 3DNET4W QSPAR (quantitative structure-property/activity relationships) approach.
Journal ArticleDOI

Dominant Negative Form of Signal-regulatory Protein-α (SIRPα/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-κB

TL;DR: In this article, a retroviral library of randomly fragmented normalized cDNA from mouse fibroblasts was screened for GSEs capable of protecting NIH3T3 cells from TNF-induced apoptosis.
Journal Article

Characterization of the pest family protein tyrosine phosphatase bdp1

TL;DR: Northern blot analysis indicated that BDP1 was expressed not only in brain, but also in colon and several different tumor-derived cell lines, and was found to differentially dephosphorylate autophosphorylated tyrosine kinases which are known to be overexpressed in tumor tissues.
Journal ArticleDOI

Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cells

TL;DR: Both IFN types reduced the expression of HER‐2 in the ovarian carcinoma cell lines OVCAR‐3, HTB‐77, 2774 and SKOV‐6, and in the SKUT‐2 endometrial carcinoma cells, but only IFN‐γ reduced proto‐oncogene expression.